Patient Power, a Partner Organization of Malecare, just released a Skype interview they made with me about some aspects of the recent AACR meeting in Chicago. I talk about the exciting results from the Phase II trial of Prostvac, a small phase II study of Pomegranate juice for men with prostate cancer as well as [...]
Curcumin is thought to have anti-cancer activity as well as to provide a synergistic effect with chemotherapy agents. Because of this Dr. Eloise Planchat of the Centre Jean Perrin, Division de Recherche Clinique, EA4231, Université d’Auvergne shared results from a prospective phase II study that assessed the impact of the combination of docetaxel (chemotherapy) plus [...]
From The AACR 2012 Meeting - Does Lycopene Effect Prostate Cancer? Yesterday’s post was about the themes I saw in cancer research. Starting today I will be reporting specific research items I saw at the meeting that specifically are important to men with prostate cancer. Dr. Peter Gann of the University of Illinois at Chicago [...]
According to an article written by Reuters some doctors have raised doubts about the efficacy of Provenge, known scientifically as sipuleucel-T. Prostate cancer vaccine Provenge has long incited passions unlike any other cancer therapy and the story seems to continue even to today. The current issue has been raised by Marie Huber, a trained scientist [...]
As I have discussed, immunological therapy will be a significant cancer treatment option in the future, but how will it actually develop and what will it look like? Provenge (sipuleucel-T), for the treatment of men with advanced prostate cancer, was the first FDA approved autologous immunologic vaccine therapy for any type of cancer. However, Provenge [...]
In one of those situations when actual clinical practice precedes the normal drug development process a recent announcement from Janssen Research & Development, LLC (Johnson & Johnson) informs that they have un-blinded their Phase 3 study, COU-AA-302, which clearly demonstrates that Zytiga (abiraterone acetate), when taken with prednisone, is effective in treating both mildly symptomatic [...]
Denosumab (Xgeva), the recently approved and only therapy that prolongs bone metastasis-free survival in men with non-metastatic castrate-resistant prostate cancer (CRPC) who are at high risk for the spread of prostate cancer metastasis to bone seems to work best in men with very rapid prostate specific antigen (PSA) kinetics. The large 1,432 man, placebo controlled, [...]
Over the years there has been discussion about using Photo Dynamic Therapy to destroy internal tumors, including prostate cancer tumors. Until now it has only been a hope since there is no way to monitor the amount of light that is actually administered to an internal tumor. We currently use laser light in combination with [...]
As a follow up to my last post about the three posters that appeared at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium meeting I am going to share with you a video interview with Dr. Chadi Nabhan. Dr. Nabhan talks about his presentation about the phase III results of the Provenge IMPACT [...]
The American Society of Clinical Oncologists (ASCO) posted on Wednesday the abstracts from the Genitourinary Conference which is scheduled for February 2-4 in San Francisco, California. Dendreon, the creator of the immunotherapy Provenge for men with metastatic castrate resistant advanced prostate cancer has three very interesting and informative posters which will appear at the conference. [...]
